Matisse Capital Arvinas, Inc. Transaction History

Matisse Capital

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$65.85 - $96.21 $509,020 - $743,703	-7,730 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$73.2 - $107.87 $14,640 - $21,574	-200 Reduced 2.52%	7,730 $635,000
Q2 2021 Aug 11, 2021	SELL	$60.45 - $84.26 $525,915 - $733,062	-8,700 Reduced 52.32%	7,930 $611,000
Q1 2021 May 14, 2021	BUY	$58.19 - $91.37 $29,095 - $45,685	500 Added 3.1%	16,630 $1.1 Million
Q4 2020 Feb 12, 2021	BUY	$20.19 - $84.93 $129,821 - $546,099	6,430 Added 66.29%	16,130 $1.37 Million
Q4 2019 Feb 12, 2020	SELL	$15.39 - $44.38 $212,382 - $612,444	-13,800 Reduced 58.72%	9,700 $399,000
Q3 2019 Oct 28, 2019	SELL	$21.55 - $27.61 $262,910 - $336,842	-12,200 Reduced 34.17%	23,500 $506,000
Q1 2019 Apr 24, 2019	SELL	$13.55 - $23.79 $79,945 - $140,361	-5,900 Reduced 14.18%	35,700 $527,000
Q4 2018 Jan 18, 2019	BUY	$11.19 - $18.56 $465,504 - $772,096	41,600 New	41,600 $535,000

230

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.09B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Matisse Capital, based on Form 13F filings with the SEC.

Stay updated on Matisse Capital with notifications on news.